Palmblad J - Search Results

1

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Birgegård G, et al. Among authors: palmblad j. Haematologica. 2004 May;89(5):520-7. Haematologica. 2004. PMID: 15136214 Clinical Trial.

2

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.

Palmblad J, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Mauritzson N, Westin J, Samuelsson J, Birgegård G. Palmblad J, et al. Int J Med Sci. 2008 Apr 13;5(2):87-91. doi: 10.7150/ijms.5.87. Int J Med Sci. 2008. PMID: 18414650 Free PMC article. Clinical Trial.

3

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.

Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Björkholm M, Löfvenberg E, Markevärn B, Merup M, Nilssson L, Palmblad J, Samuelsson J, Birgegård G. Ejerblad E, et al. Among authors: palmblad j. Hematology. 2013 Jan;18(1):8-13. doi: 10.1179/1607845412Y.0000000023. Epub 2012 Sep 14. Hematology. 2013. PMID: 22990042 Free article. Clinical Trial.

4

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.

Merup M, Kutti J, Birgergård G, Mauritzson N, Björkholm M, Markevärn B, Maim C, Westin J, Palmblad J; Swedish National Study Group on Chronic Myeloproliferative Disorders. Merup M, et al. Among authors: palmblad j. Med Oncol. 2002;19(2):79-86. doi: 10.1385/mo:19:2:79. Med Oncol. 2002. PMID: 12180484 Clinical Trial.

5

The defective stimulus-response coupling for oxidative reactions in neutrophils from patients with polycythemia vera.

Samuelsson J, Palmblad J. Samuelsson J, et al. Among authors: palmblad j. Acta Haematol. 1996;96(4):264-5. doi: 10.1159/000203800. Acta Haematol. 1996. PMID: 8922499 Free article. No abstract available.

6

[New recommendations on chronic myeloproliferative diseases. New knowledge must yield new practice].

Merup M, Löfvenberg E, Palmblad J. Merup M, et al. Among authors: palmblad j. Lakartidningen. 2009 Jan 14-20;106(3):98-9. Lakartidningen. 2009. PMID: 19248458 Swedish. No abstract available.

7

Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders.

Samuelsson J, Forslid J, Hed J, Palmblad J. Samuelsson J, et al. Among authors: palmblad j. Br J Haematol. 1994 Jul;87(3):464-70. doi: 10.1111/j.1365-2141.1994.tb08299.x. Br J Haematol. 1994. PMID: 7993785

8

[Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way].

Merup M, Palmblad J. Merup M, et al. Among authors: palmblad j. Lakartidningen. 2009 Dec 2-8;106(49):3342, 3344-6. Lakartidningen. 2009. PMID: 20104733 Review. Swedish. No abstract available.

9

Defective neutrophil oxidative metabolism in polycythemia vera is associated with an impaired activation of phospholipase D.

Samuelsson J, Palmblad J. Samuelsson J, et al. Among authors: palmblad j. Ann N Y Acad Sci. 1997 Dec 15;832:13-20. doi: 10.1111/j.1749-6632.1997.tb46233.x. Ann N Y Acad Sci. 1997. PMID: 9704033 Review. No abstract available.

10

Stimulus-specific defect in platelet aggregation in polycythemia vera.

Le Blanc K, Berg A, Palmblad J, Samuelsson J. Le Blanc K, et al. Among authors: palmblad j. Eur J Haematol. 1994 Sep;53(3):145-9. doi: 10.1111/j.1600-0609.1994.tb00662.x. Eur J Haematol. 1994. PMID: 7925857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

316 results

Search Page

Filters